Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will participate in the Canaccord Genuity Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. EDT. The company’s presentation will be webcast live, with access via Madrigal’s Investor Relations Events and Presentations page, and a replay available after the event.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Inducement awards | Neutral | -1.7% | Equity awards granted to ten new non-executive employees under the inducement plan |
| Jul 16 | Earnings scheduling | Neutral | -0.9% | Company scheduled second-quarter financial results and a management webcast |
| Jul 13 | Patent grants | Positive | -1.1% | USPTO issued three patents covering resmetirom treatment regimens and administration |
| Jul 06 | Inducement awards | Neutral | +3.0% | Equity awards granted to seven new non-executive employees under the inducement plan |
| Jul 01 | Partnership milestone | Positive | +2.7% | Ribo and Madrigal nominated a MASH candidate and began IND-enabling studies |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements produced mixed reactions, with three of five events diverging from the announcement sentiment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
